MTOR and hepatocellular carcinoma: Alpha-fetoprotein (AFP), the first serum biomarker of HCC, was discovered in 1963, and it has been demonstrated that it activates AKT/mTOR signaling to promote CXCR4 expression and migration of hepatoma cells, while several other protein biomarkers have been identified and utilized into clinical practice since then [159].